Abstracts tagged "auto-immunity and autoantibodies"

Abstract Number: 2795 • 2018 ACR/ARHP Annual Meeting
IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus
Huixian Hong¹, Qi Wu², PingAr Yang², Bao Luo³, Jun Li⁴, Hao Li⁵, Daniel Cua⁶, Hui-Chen Hsu² and John D. Mountz⁷, ¹University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ³DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁵Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁷University of Alabama at Birmingham, Devision of Clinical Immunology and Rheumatology; University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: IL-23 is currently a target for several forms of autoimmune diseases, yet its role in promoting pathogenic autoantibody development is less clear. IL-23 was…
Abstract Number: 1853 • 2015 ACR/ARHP Annual Meeting
Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
Asiya Chida¹, Kevin Cashman¹, Scott Jenks², Louise Hartson¹, Youliang Wang¹, Quan-Zhen Li Li^3,4, Chandra Mohan⁵ and Ignacio Sanz^6,7, ¹Medicine, Emory University, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Biomedical Engineering, University of Houston, Houston, TX, ⁶Rheumatology, Emory University, Atlanta, GA, ⁷Medicine/Rheumatology, Emory University, Atlanta, GA
Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique…
Abstract Number: 2526 • 2013 ACR/ARHP Annual Meeting
An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY iCHIP™
Chaim Putterman¹, Irene Blanco², Nicole Jordan³, Yves Renaudineau⁴, Vered Daniel Carmi⁵, Rachel Sorek⁵, Ornit Cohen-Gindi⁵, Miriam Lerner⁵, D. Scott Batty⁵, Idan Tamir⁵ and Irun R Cohen^5,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁵ImmunArray, Rehovot, Israel, ⁶Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, recurrent, and potentially fatal multisystem inflammatory disorder mainly affecting women. SLE patients produce antibodies to many different self-antigens,…
Abstract Number: 1502 • 2013 ACR/ARHP Annual Meeting
Antibodies To Anti-Type -3 Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy-2-Noneal-Modified and 60-Kda Ro
Valerie Harris¹, Biji T. Kurien², R. Hal Scofield³, Timothy Gross⁴ and Mary Girton⁵, ¹Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: In Sjörgen’s Syndrome, an autoimmune disease, the lacrimal and salivary glands are the primarily affected glands. Previous studies have proposed autoantibodies that target type-3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].